Farnesoid X receptor (FXR; gene symbol NR1H4) is a bile-acid-sensing nuclear receptor that coordinates enterohepatic bile-acid flux, lipid handling, and inflammatory tone.[1][2] Most validated FXR biology comes from liver and intestine, where ligand-dependent FXR signaling induces SHP/NR0B2 and FGF19 (FGF15 in rodents), then suppresses CYP7A1-mediated bile-acid synthesis as a canonical feedback circuit.[1:1][3]
Neurodegeneration relevance is increasingly framed as a systems problem rather than a single CNS receptor problem: gut microbial metabolism alters bile-acid pools, bile-acid pools alter FXR/TGR5 signaling, and these pathways can reshape peripheral and central inflammatory set-points, lipid metabolism, and neuronal stress vulnerability.[4][5][6] In parallel, human dementia metabolomics studies consistently show altered circulating and brain bile-acid patterns in Alzheimer's disease, including shifts toward secondary bile acids associated with worse cognition.[7][8]
Current evidence strength is uneven. The strongest data are: (1) core FXR pathway biology in liver-intestine systems, (2) bile-acid alterations in AD/PD cohorts, and (3) microbiome-causality experiments in PD-like models. Direct proof that CNS FXR modulation alone changes human neurodegeneration trajectories remains limited, so mechanistic claims should be treated as graded hypotheses.[1:2][4:1][7:1]
The best-established FXR module is intestinal FXR -> FGF19 -> hepatic FGFR4/beta-Klotho -> CYP7A1 suppression.[1:3][3:1] This loop changes bile-acid composition and recirculation, which in turn modifies which ligands can engage FXR or TGR5-linked signaling nodes in peripheral tissues.[3:2][9]
Even if direct CNS FXR activity is modest compared with hepatic signaling, this peripheral loop can still matter for neurobiology because bile acids and immune mediators are circulating signals with access to vascular, barrier, and glial biology.[2:1][4:2]
CNS-specific data are narrower but biologically suggestive. FXR mRNA/protein expression has been reported in primary astrocyte preparations, and preclinical microglial studies suggest FXR-linked anti-inflammatory effects in vitro.[10][11] These data support plausibility, not clinical proof.
For translational planning, a conservative interpretation is:
Multiple cohorts report bile-acid metabolome changes in AD and mild cognitive impairment. A replicated pattern includes reduced primary bile-acid signatures with relative enrichment of secondary bile-acid conversion products associated with cognitive decline.[7:2][8:1] These observations align with a gut-liver-brain disturbance model in which microbiome and bile-acid dysregulation contribute to AD-relevant inflammatory and metabolic stress.
Mechanistically, the main connection points to AD biology are:
Because these are predominantly associative and preclinical bridges, they should be interpreted as mechanism-informed risk pathways, not confirmed FXR-driven disease causation.
PD offers stronger microbiome-causality support. In alpha-synuclein overexpression mouse models, germ-free or microbiome-manipulated conditions alter motor deficits and microglial activation, showing gut microbial states can drive disease-relevant phenotypes.[5:1] Additional transplantation studies in toxin models support the directionality of microbiota -> inflammation -> motor/neuronal outcomes.[13][14]
FXR is relevant because microbial composition shapes bile-acid pools, and bile-acid pools shape FXR/TGR5 signaling context. In PD framing, this creates a plausible chain:
microbiome dysbiosis -> bile-acid remodeling -> altered FXR/TGR5 signaling set-point -> inflammatory and metabolic pressure on vulnerable dopaminergic systems.[4:4][5:2][13:1]
This does not yet prove that an FXR agonist modifies PD progression in humans; it does justify biomarker-stratified mechanistic trials.
FXR and NF-kappaB pathways have reciprocal antagonism in established inflammatory biology, with FXR activation suppressing pro-inflammatory transcriptional programs in multiple contexts.[15][16] Although much of this evidence is hepatic/macrophage-focused, the same circuit logic is relevant to CNS innate-immune responses and glial activation states.
In practical neurodegeneration terms, FXR-linked anti-inflammatory tone is most likely to be useful where pathology is driven by chronic, self-reinforcing inflammatory loops rather than acute inflammatory bursts. This aligns with long-horizon diseases like AD, PD, progressive supranuclear palsy, and corticobasal degeneration, where sustained microglial/astroglial activation contributes to progression burden.[6:2][17][18]
Direct FXR-CBS/PSP evidence is sparse; however, a hypothesis-driven bridge is reasonable because CBS/PSP are 4R-tau disorders with major glial and inflammatory components.[17:1][18:1]
A credible CBS/PSP FXR program should show more than symptom fluctuation. Minimum translational signals:
Without these elements, FXR relevance remains conceptual.
Obeticholic acid is the most clinically advanced FXR agonist in liver disease programs and demonstrates clear on-target biology, but adverse effects including pruritus and LDL-C increases are recurrent and must be actively managed.[19][20] Nonsteroidal agonists such as cilofexor and tropifexor have shown target engagement and metabolic effects in NASH-phase studies, with mixed efficacy and expected tolerability constraints.[21][22]
For neurodegeneration repurposing, key constraints are:
Intestine-focused FXR modulation is attractive because it may preserve FGF19/bile-acid axis effects while limiting systemic exposure and toxicity.[3:3][23] This approach is mechanistically aligned with a gut-brain strategy and may be better suited to chronic neurodegeneration cohorts if efficacy signals emerge.
Given pathway complexity, FXR approaches are likely adjunctive rather than standalone. Rational combinations include:
Combination trials should prioritize mechanistic enrichment (baseline bile-acid dysregulation, inflammatory signatures) instead of broad unselected enrollment.
A disciplined FXR program should therefore proceed as biomarker-anchored, adaptive translation rather than immediate broad efficacy deployment.
Chiang JYL. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. FASEB J. 2016. ↩︎ ↩︎ ↩︎ ↩︎
Gadaleta RM, van Mil SWC. Farnesoid X receptor in the gut-liver axis and metabolic regulation. Nat Rev Gastroenterol Hepatol. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Li T, Chiang JYL. Bile acid signaling in metabolic disease and potential neurologic relevance. Cell Mol Gastroenterol Hepatol. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016. ↩︎ ↩︎ ↩︎ ↩︎
Fang P, Kazmi SA, Jameson KG, Hsiao EY. The microbiome as a regulator of neurodegenerative disease. Nat Rev Neurol. 2020. ↩︎ ↩︎ ↩︎
MahmoudianDehkordi S, Arnold M, Nho K, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease. Alzheimers Dement. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Baloni P, Funk CC, Yan J, et al. Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer's disease. Alzheimers Dement. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Duboc H, Taché Y, Hofmann AF. 'The bile acid TGR5 membrane receptor: from basic research to clinical application'. Dig Liver Dis. 2014. ↩︎
Hu Y, Li C, Wang X, et al. Identification of the expression of farnesoid X receptor in astrocytes. Neurochem Res. 2021. ↩︎
Hu J, Zhang Y, Jiang X, et al. Ganoderic acid A attenuates LPS-induced neuroinflammation in BV2 microglia by activating farnesoid X receptor. Acta Pharmacol Sin. 2021. ↩︎ ↩︎
Nho K, Kueider-Paisley A, MahmoudianDehkordi S, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease. Sci Rep. 2019. ↩︎
Zhu G, Zhao J, Zhang H, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppression of LPS-TLR4 signaling. Microbiome. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Sun Z, Li Y, Wang H, et al. Gut microbiota dysbiosis contributes to alpha-synuclein-related pathology in a mouse model of Parkinson's disease. Gut Microbes. 2024. ↩︎ ↩︎
Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008. ↩︎ ↩︎
Wang Y, Chen W, Moore DD, Huang W. FXR inhibits macrophage inflammatory responses and endotoxin-related injury. PLoS One. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Höglinger GU, Respondek G, Stamelou M, et al. 'Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria'. Mov Disord. 2017. ↩︎ ↩︎
Kouri N, Whitwell JL, Josephs KA, et al. 'Corticobasal degeneration: a pathologically distinct 4R tauopathy'. Nat Rev Neurol. 2011. ↩︎ ↩︎
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT). Lancet. 2015. ↩︎
Younossi ZM, Ratziu V, Loomba R, et al. 'Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial'. Lancet. 2019. ↩︎
Patel K, Harrison SA, Elkhashab M, et al. 'Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial'. Hepatology. 2020. ↩︎
Francque S, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021. ↩︎
Zhou H, Hylemon PB. Fexaramine as an intestine-specific farnesoid X receptor agonist. Drug Discov Today. 2025. ↩︎